KDR and neoplasm: Human NSCLC angiogenesis is triggered by a tumor VEGF/VEGFR2 autocrine feed-forward loop which amplifies VEFG secretion by tumor cells and when this loop is inhibited, the tumor changes to a proliferative phenotype that sensitizes tumor cells to MAPK inhibition [31].